News

Second Quarter Summary: Financial highlights: Operating income of $6.2 million Revenue by market: Therapeutic: Cardiovascular – $9.6 million Ophthalmology – $3.7 million Other Markets – $2.9 million Diagnostic

Osiris said the technology being offered would allow companies involved in the screening of pharmaceutical compounds the ability to determine certain critical metabolic effects on viable human cells.

The studies conducted by university researchers have demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90% with no evidence of detrimental changes to cell viability.

The study suggests that two components of AMF-1, itself a fraction of PRB Pharmaceuticals over the counter flu medication VIRA 38, are effective in inhibiting a 3C-like enzyme,

Data from the multi-center phase II trial of NX-1207, Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), has led the company to suggest it

The company’s study of Thymitaq in patients with liver cancer failed to achieve its primary target of a survival benefit versus doxorubicin, an antibiotic often used in the

Radilex is currently in development for treating toxic radiation exposure, including Acute Radiation Sickness. Recent testing of the drug using Total Body Irradiation (TBI) in an animal model

The study was designed to investigate the efficacy and safety of Risperdal Consta (risperidone) in patients with schizophrenia or other psychotic disorders who required a change of treatment.

Results of the study indicate that endovascular therapy can lead to significant recovery for patients suffering the most severe effects of aneurysm bleeds, or subarachnoid hemorrhage (SAH). In